Parkin disease and the Lewy body conundrum

Movement Disorders

Volumn 28, Issue 6, 2013, Pages 702-704

  Doherty, Karen M ^a   Hardy, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; BRAIN DEPTH STIMULATION; BRAIN STEM; CORPUS STRIATUM; EXON; FRONTOTEMPORAL DEMENTIA; GAIT DISORDER; GENE MUTATION; HETEROZYGOTE; HIPPOCAMPUS; HUMAN; LEWY BODY; LOCUS CERULEUS; MEYNERT BASAL NUCLEUS; MISSENSE MUTATION; MOTONEURON NUCLEUS; ONSET AGE; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN FUNCTION; QUALITY CONTROL; RETICULAR FORMATION; SUBSTANTIA NIGRA; VAGUS NERVE;

ANIMALS; HUMANS; LEWY BODIES; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES;

EID: 84879601226     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25486     Document Type: Article

References (28)

1. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27:831-842.
2. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010;133:1128-1142.
3. Deas E, Wood NW, Plun-Favreau H. Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta 2011;1813: 623-633.
4. Yamamura Y, Kuzuhara S, Kondo K, et al. Clinical, pathologic and genetic studies on autosomal recessive early-onset parkinsonism with diurnal fluctuation. Parkinsonism Relat Disord 1998;4:65-72.
5. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
6. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15:884-888.
7. van de Warrenburg BPC, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-557.
8. Farrer M, Chan P, Chen R, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001;50:293-300.
9. Mori H, Hattori N, Mizuno Y. Genotype-phenotype correlation: familial Parkinson disease. Neuropathology 2003;23:90-94.
10. Gouider-Khouja N, Larnaout A, Amouri R, et al. Autosomal recessive parkinsonism linked to parkin gene in a Tunisian family. clinical, genetic and pathological study. Parkinsonism Relat Disord 2003;9:247-251.
11. Sasaki S, Shirata A, Yamane K, Iwata M. Parkin-positive autosomal recessive juvenile Parkinsonism with alpha-synuclein-positive inclusions. Neurology 2004;63:678-682.
12. Pramstaller PP, Schlossmacher MG, Jacques TS, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005;58:411-422.
13. Torres L, Cornejo M, Mata I, et al. A novel PARK2 mutation in a Peruvian family: clinical and pathological characteristics. Mov Disord 2011;26:s311-s312.
14. Orimo S, Amino T, Yokochi M, et al. Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 2005;20:1350-1353.
15. Doherty KM, Silveira-Moriyama L, Parkkinen L, et al. Parkin disease-a clinicopathological entity [serial online]? JAMA Neurol 2013;4:1-9.
16. Miyakawa S, Ogino M, Funabe S, et al. Lewy body pathology in a patient with a homozygous Parkin deletion. Mov Disord 2013;28:388-391.
17. Parkkinen L, Soininen H, Laakso M, Alafuzoff I. alpha-Synuclein pathology is highly dependent on the case selection. Neuropathol Appl Neurobiol 2001;27:314-325.
18. Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 2009;68:816-822.
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(pt 5):2283-2301.
20. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
21. Deng H, Le WD, Hunter CB, et al. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006;63:273-277.
22. Mizutani Y, Yokochi M, Oyanagi S. Juvenile parkinsonism: neuropathological findings of 9 cases. Gendaiiryou (Tokyo) 1993;25:11-17.
23. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994; 44:437-441.
24. Sriram SR, Li X, Ko HS, et al. Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet 2005;14:2571-2586.
25. Suzuki M, Hattori N, Orimo S, et al. Preserved myocardial [123I]metaiodobenzylguanidine uptake in autosomal recessive juvenile parkinsonism: first case report. Mov Disord 2005;20:634-636.
26. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv Neurol 1993;60: 600-608.
27. Richardson JR, Caudle WM, Guillot TS, et al. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Toxicol Sci 2007;95:196-204.
28. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984;225:1480-1482.